Journal of Microwave Surgery
Online ISSN : 1882-210X
Print ISSN : 0917-7728
ISSN-L : 0917-7728
Current issue
Showing 1-1 articles out of 1 articles from the selected issue
Original Article
  • Toru Beppu, Shingo Yamashita, Masakazu Yamamoto, Masahiro Yoshida, Hid ...
    Type: Original
    2020 Volume 37 Issue 5 Pages 1-6
    Published: 2020
    Released: August 09, 2020
    Microwave coagulation therapy (MCT) for liver tumors had initially developed in Japan and now is spreading worldwide. Microwave thermosphere ablation is a new concept using cooling antenna to create a larger spherical necrotic area. Recently, the indications of MCT is spreading from hepatocellular carcinoma to liver metastases. MCT is recommended only for patients with unresectable colorectal liver metastases (CRLM); ≤ 3cm and ≤ 3 nodules in combination with systemic chemotherapy. MCT has some benefits compared with radiofrequency ablation: 1) Shorter ablation time; 2) Lower local recurrence rate; 3) better disease-free and overall survival; 4) Complete necrosis even for the tumor adjacent to the large vessels; and 5) Similar complication rates. In summary, MCT is evolving as one of the promising local treatments for liver metastases; however, a randomized control trial is required to create solid evidences.